REFERENCES
1. Tunstall O, Bhatnagar N, James B, et al. Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.Br J Haematol. 2018;182(2):200-211.
2. Johann Hitzler M, FRCP(C), FAAPMoira Garraus, MD. Transient Myeloproliferative Disorder of Down Syndrome. https://www.uptodate.com/contents/transient-myeloproliferative-disorder-of-down-syndrome. Published March 2020. Updated March 2020. Accessed January 25 2021, 2021.
3. Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr Hematol Malig Rep. 2016;11(5):333-341.
4. Brink DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol. 2006;13(5):256-262.
5. Watanabe K. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome. Pediatr Int.2019;61(3):222-229.
6. Kikuchi A, Tamura N, Ishii K, et al. Four cases of fetal hypoechoic hepatomegaly associated with Trisomy 21 and transient abnormal myelopoiesis. Prenat Diagn. 2007;27(7):665-669.
7. Rizzo A, Perotti G, Fiandrino G, Spinillo A, Stronati M, Iasci A. Prenatal diagnosis of transient abnormal myelopoiesis in three fetuses with Down syndrome: heterogeneous ultrasonographic findings and outcomes. Ultrasound Obstet Gynecol. 2018;51(3):412-413.
8. Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer. 2008;8(4):279-287.
9. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. Blood. 2015;126(8):943-949.
10. Roy A, Roberts I, Norton A, Vyas P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol.2009;147(1):3-12.
11. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971.Blood. 2011;118(26):6752-6759; quiz 6996.
12. Flasinski M, Scheibke K, Zimmermann M, et al. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. Blood Adv. 2018;2(13):1532-1540.
13. Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome.Crit Rev Oncog. 2011;16(1-2):25-36.
14. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481.Blood. 2006;107(12):4606-4613.
15. Bull MJ, Committee on G. Health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393-406.